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Abstract
Background:  Many patients experience difficulties in following treatment recommendations. This study's
objective is to identify nonadherence risk profiles regarding medication (antidepressants, antihypertensives, and
oral hypoglycemics) from a combination of patients' socio-demographic characteristics, morbidity presented
within general practice and medication characteristics. A n  a d d i t i o n a l  o b j e c t i v e  i s  t o  e x p l o r e  d i f f e r e n c e s  i n
nonadherence among patients from different general practices.
Methods: Data were obtained by linkage of a Dutch general practice registration database to a dispensing
registration database from the year 2001. Subjects included in the analyses were users of antidepressants (n =
4,877), antihypertensives (n = 14,219), or oral hypoglycemics (n = 2,428) and their GPs. Outcome variables were:
1) early dropout i.e., a maximum of two prescriptions and 2) refill nonadherence (in patients with 3+
prescriptions); refill adherence < 80% was considered as nonadherence. Multilevel modeling was used for
analyses.
Results:  Both early dropout and refill nonadherence were highest for antidepressants, followed by
antihypertensives. Risk factors appeared medication specific and included: 1) non-western immigrants being more
vulnerable for nonadherence to antihypertensives and antidepressants; 2) type of medication influencing
nonadherence in both antihypertensives and antidepressants, 3) GP consultations contributing positively to
adherence to antihypertensives and 4) somatic co-morbidity influencing adherence to antidepressants negatively.
There was a considerable range between general practices in the proportion of patients who were nonadherent.
Conclusion: No clear risk profiles for nonadherence could be constructed. Characteristics that are correlated
with nonadherence vary across different types of medication. Moreover, both patient and prescriber influence
adherence. Especially non-western immigrants need more attention with regard to nonadherence, for example
by better monitoring or communication. Since it is not clear which prescriber characteristics influence adherence
levels of their patients, there is need for further research into the role of the prescriber.
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Background
Adherence to medication can be defined as the extent to
which patients follow the instructions they are given for
prescribed treatments [1]. Many patients experience diffi-
culties in following treatment recommendations [2]. As a
result levels of adherence are often far from optimal, espe-
cially in patients with chronic diseases. Nonadherence is
supposed to have a negative impact on patient outcomes
in terms of medical and psychosocial complications of
disease, reduction in patients' quality of life and waste of
health care resources [2,3].
Adherence rates have hardly changed over the last decades
[4]. In medical practice, patients are usually reluctant to
talk about adherence. Therefore, it will be helpful to iden-
tify nonadherent patients by their risk profiles. Since
adherence problems are influenced by many factors, risk
profiles should include patient-related, disease and treat-
ment characteristics as well as attributes of the healthcare
system [2,5,6]. Patient-related characteristics that, for
example, have been correlated with nonadherence are
socio-economic status, etnicity and social support [2].
Although many studies have been performed on determi-
nants of nonadherence, no clear picture emerges of the
"nonadherent" patient [3]. The WHO-report suggested
that factors associated with nonadherence differ by type of
disease [2]. However, there is hardly any research that uses
comparable data on different diseases [7]. So far, differ-
ences can as much be the result of using different outcome
measures, different correlates, different patients or the fact
that, for example, adherence to antihypertensives is influ-
enced by other factors than antidepressants. A reason why
patient risk profiles may be hard to construct, is that
adherence is not only determined by patient characteris-
tics but also by variation between prescribers in adherence
levels of their patients. While it is obvious that patients
differ in level of adherence, it is not clear to what extent
prescribers vary in the proportion of nonadherent
patients. This is because, up to now, patients have been
the main focus of research.
This study's objective is to identify risk profiles regarding
nonadherence from a combination of patients' socio-
demographic characteristics, morbidity presented within
general practice and medication characteristics. For this




3) type 2 diabetes.
These diseases are known for their lifelong or long-term
medication need and identified as high risk areas regard-
ing adherence [2]. For all three diseases the same source
population as well as the same outcome measures will be
used. An additional objective is to explore differences in




Data for this study were obtained by linkage of routine
registration data collected in general practice to a dispens-
ing registration database. In the Netherlands, every indi-
vidual is listed in a general practice. In 2001, the
Netherlands had 7,763 GPs [8]. GP data were used from
the Second Dutch National Survey of General Practice
(DNSGP-2). This representative survey of 104 Dutch gen-
eral practices (195 GPs) and their 385,461 patients was
performed by NIVEL (Netherlands Institute for Health
Services Research) in cooperation with RIVM (National
Institute for Public Health) in 2001 [9]. Registration data
were collected on all medical consultations, prescriptions,
and referrals. Furthermore, 76.5% of the patients
responded to a census with questions on demographic
data, such as age, gender, health insurance, educational
level, and perceived health. Most census data were col-
lected in 2000. Pharmacy dispensing data were collected
by the Foundation for Pharmaceutical Statistics (SFK).
The SFK network represents 86.5% of all public pharma-
cies in the Netherlands. Medication histories of Dutch
pharmacies are virtually complete because almost all
patients fill their prescription at a single pharmacy and
prescriptions written by GPs and medical specialists are
included. Data from both sources were linked by research-
ers from Utrecht University. In short, 110,102 patients
from 83 general practices participating in DNSGP-2 were
identified in 112 pharmacies who delivered data to SFK.
Linking was based on the patient's gender, year of birth,
postal code and prescription characteristics. Prescription
characteristics were used in the linking process because
the other three linking keys did not provide unique
matches for all patients. Since both DNSGP-2 and SFK
included data on patients' medication it was possible to
compare medication profiles (type of medication, date of
prescribing) as far as prescribed by the GP. The linking
procedure is described and discussed in more detail else-
where [10].
The study was carried out according to Dutch legislation
on privacy. The privacy regulation of the study was
approved by the Dutch Data Protection Authority.
According to Dutch legislation, obtaining informed con-
sent is not obligatory for observational studies.BMC Health Services Research 2007, 7:51 http://www.biomedcentral.com/1472-6963/7/51
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Subjects
Subject to the study were patients who used antidepres-
sants, antihypertensives or oral hypoglycemics in 2001 for
whom a successful linking was achieved and who had no
missing data on the included variables. Data were availa-
ble for 7,365 users of antidepressants, 20,004 users of
antihypertensives and 3,548 users of oral hypoglycemics.
In total, 2,488 users of antidepressants had missing data
on sociodemographic variables and morbidity (33.8%);
the same was true for 5,785 users of antihypertensives
(28.9%) and 1,120 users of oral hypoglycemics (31.6%).
Patients with missing data did not differ from the
included patients on nonadherence measures.
Measures
Nonadherence
Two measures for nonadherence were calculated: 1) early
dropout and 2) refill of prescriptions ('refill nonadher-
ence'). Early dropout was defined as a maximum of two
prescriptions in 2001 and no preceding prescriptions in
the last half of 2000 or subsequent prescriptions in the
first half of 2002. Drop-out rates for oral hypoglycemics
were low (n = 82). Therefore, this measure was only calcu-
lated for antihypertensives and antidepressants.
Regarding refill nonadherence we adopted a procedure
developed by the Utrecht Institute for Pharmaceutical Sci-
ences (UIPS) to calculate nonadherence among chronic
users of medication. To calculate refill nonadherence we
first defined the date of the first prescription in 2001 as
well as the end date of the last prescription initiated in
2001. This end date usually was in 2002. Once the start
and end date were determined, we calculated the number
of days for which dosages were dispensed between the
start and the end date divided by the total number of days
between the start and end date. Following other studies, a
patient with compliance below 80% was considered to be
nonadherent [7,11]. We calculated this measure for
patients with chronic medication, i.e. those who had at
least three prescriptions in 2001. Of course, we preferred
to use cut-off points for which evidence has shown its rel-
evance for outcomes. However, strong evidence for the
best cut-off point per disease is not yet available. There-
fore, we took the same cut-off point for all three types of
medication: 80%. The reason to choose for 80% is two-
fold. First, we expected risk profiles to be more clear using
this cut-off point, compared to, for example, a cut-off
point of 90%- 95% or a continuous measure. Second, a
pragmatic reason was that if thresholds < 80% were used,
the absolute number of patients in the nonadherent
groups was low, especially for oral hypoglycemics.
Socio-demographic characteristics
Gender and age were included. As indicators for social sta-
tus we included educational level (0=precollege educa-
tion; 1 = college/university), type of health insurance (0 =
public; 1 = private) and employment status (0 = not
employed or in school; 1 = employed or in school). Fur-
thermore, first and second generation immigrants from
non-western countries were compared to the combined
population of western immigrants and the indigenous
Dutch population (0 = western; 1 = non-western). Finally,
we included a variable that reflects whether or not the
patient lives together (0 = living alone; 1 = living with
spouse and/or children).
Medication
All prescriptions in the database were coded using the
Anatomical Therapeutical Chemical (ATC) coding system
[12]. Antidepressants (ATC-code N06A) were divided into
three categories: TCAs (N06AA), SSRIs (N06AB) and other
antidepressants (N06AF/N06AX). The following antihy-
pertensives were distinguished: diuretics (C03), beta-
blockers (C07), ACE-inhibitors/angiotensin II receptor
antagonists (C09) and other (C02/C08). For oral
hypoglycemics no such distinction was made; these drugs
closely resemble each other when it comes to adverse reac-
tions, effectiveness etc (oral information EH). We tested
whether adherence to biguanides and sulfonylureas
indeed did not differ. We found no significant differences.
Patients who used insulin were not included in the analy-
sis. As a proxy for complex medication regime the sum of
different full ATC-codes was used.
Morbidity presented in general practice
The contact registration in the DNSGP-2 database pro-
vided information on the diagnoses for which the patient
consulted the GP. Every contact was coded according to
the International Classification for Primary Care (ICPC)
[13]. We assessed whether the patient visited the GP for
the main indications for respectively antidepressants,
antihypertensives, and oral hypoglycemics: depression
(P03/P76) or anxiety (P01/P74), hypertension (ICPC:
K85, K86, K87), and diabetes mellitus (T90). Moreover,
we assessed whether patients visited their GP during the
year of registration for related complaints such as other
cardiovascular diseases (K70–K90, excluding hyperten-
sion), and hypercholesterolemia and, for antidepressants,
other psychological diagnoses in the ICPC-chapter P. The
total number of other chronic diseases for which the
patient contacted the GP in 2001 was also assessed. The
definition of chronic diseases was adopted from earlier
studies [14]. The disease under study and related diseases
were excluded from the definition; they were already cov-
ered by the variables described above. While the database
included information on prescriptions by medical special-
ists, information on consultation of medical specialists is
lacking in the database. We also included information on
self-perceived health, which was asked in the patient cen-
sus (0 = poor to moderate; 1 = good to excellent). Finally,BMC Health Services Research 2007, 7:51 http://www.biomedcentral.com/1472-6963/7/51
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the total number of contacts the patient had with the GP
in 2001 was calculated.
Analysis
Chi-square tests and student's t-test were used to analyze
differences in basic characteristics between patients who
were adherent and patients who were not. These bivariate
analyses did not take into account the clustered nature of
our data. We did use the nested structure of the data – our
patients were sampled from general practices – in the mul-
tivariate analyses. We fitted a binomial 2nd order multi-
level model with two levels (practice and patient) for each
of the five dependent variables of interest (two times early
dropout, three times refill nonadherence). All independ-
ent variables (sociodemographics, use of medication and
health and morbidity) were included in the same multi-
level model, so all independent variables in the multilevel
analyses were adjusted for each other.
As we stated before, the 80% cut-off point for nonadher-
ence is arbitrary [7]. Therefore, we also estimated the same
models for refill adherence using 70% (despite low num-
bers of patients for oral hypoglycemics) and 90% as cut-
off points. Moreover, we used a linear model to estimate
correlates between the independent variables and Nonad-
herence measured as a continous variable. The results of
these analyses are not presented in tables, but they are dis-
cussed related to the results of the analyses using the 80%
cut-off point.
Multilevel analysis was also used to calculate the probabil-
ity that a patient is refill nonadherent at the practice level.
We expressed this as the proportion of nonadherent
patients in the practice. We used an empty model only
including the dependent variables and the two levels
(patient and practice). In that way the "entrance" proba-
bility of a patient to be nonadherent in a certain practice
is known. Such model also allows to calculate the 95%-
confidence interval for this probability. This interval
shows the range between the minimum and maximum
probability to be nonadherent at the practice level. The
model was fitted for each drug therapy.
All data were analyzed with SPSS version 11.0 and 'multi-
level models for windows' (MLwin).
Results
Antidepressants
In total 4,877 patients were eligible for analyses of whom
928 patients received one or two prescriptions in 2001.
556 of them could be identified as an early dropout
because they received no prescription for antidepressants
the half year before and after 2001. This implies that
11.4% of the 4,877 included patients were early dropouts.
Women were less likely and non-western immigrants
were more likely to be an early dropout (Table 1/Addi-
tional file 1). Users of TCAs were overrepresented among
the early dropouts. Early dropouts were more likely to
consult their GP for depression and anxiety than other
patients; the opposite holds for neurasthenia and other
psychological problems. On average, early dropouts pre-
sented more other chronic diseases to their GP than other
users.
In total, 3,777 patients received three or more prescrip-
tions in 2001; for these patients refill adherence was cal-
culated. Almost a quarter of them (24.6%) showed a refill
rate < 80%. We found that non-western immigrants were
more likely to be nonadherent (Table 1/Additional file 1).
Refill nonadherence was highest for SSRIs and lowest for
TCAs. A complex medication regime (i.e. more different
types of medication) was moderately negatively associ-
ated with refill nonadherence. Patients were more likely to
be nonadherent the more other chronic complaints they
had. Patients who rate their health as good-excellent have
lower compliance. These two last findings show that those
who feel good, are less likely to take their medication
regardless of their actual disease pattern. The analyses
using other cut-off points (70%, 90%) and the analysis
using refill adherence as a continuous dependent variable
all showed identical significant effects for ethnicity and
other chronic complaints. They did not yield any new sig-
nificant relationship, except that both the analysis with
the 70% cut-off point and the analysis with the continu-
ous measure showed that patients who consulted their GP
for anxiety were less often nonadherent.
Antihypertensives
In total 2,109 patients received only one or two prescrip-
tions in 2001; 813 of them could be identified as an early
dropout because they had no prescriptions in the half year
before and/or after 2001. Therefore, 5.7% of the 14,219
patients included in the analyses was considered to be an
early dropout. Compared to continuers, early dropouts
were more often younger, female, higher educated or had
a non-western background (Table 2/Additional file 2).
Users of diuretics were more likely to be an early dropout
than patients who used any of the other antihyperten-
sives. The chance that early dropouts consulted their GP
for hypertension and related co-morbidity was lower than
that of other users of antihypertensives. Moreover, early
dropouts presented more other chronic complaints in
general practice, but they used less different types of med-
ication. Since early dropouts proved to be clearly younger
than other patients, we also performed an analysis in
which only patients > 40 years were included. The effects
for this population proved to be weaker, but still were sig-
nificant (results not in table).BMC Health Services Research 2007, 7:51 http://www.biomedcentral.com/1472-6963/7/51
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Refill adherence was calculated for the 12,110 patients
who received three or more prescriptions in 2001. Refill
adherence < 80% was found for 11.6% (n = 1,405) of
them. Patients who used beta blockers, ace-inhibitors/A2-
antagonists and other antihypertensives (C02/C09) were
less likely to be nonadherent than users of diuretics. More-
over, patients with a complex medication regime were less
likely to be nonadherent to antihypertensive medication;
the effect, however, is moderate. Finally, chronic users
who consulted their GP for hypertension or diabetes were
more likely to take their medication as prescribed. In addi-
tion, both the analysis using the 90% cut-off point and the
analysis using refill adherence as a continuous dependent
variable showed that non-western immigrants were less
adherent and that patients who live together are more
likely to be adherent.
Oral hypoglycemics
Of the 2,428 patients eligible for analysis 90.4% (n =
2,194) had three or more prescriptions in 2001. Refill
adherence < 80% was found for 6.9% (n = 152) of them.
Nonadherent patients hardly differed from adherent
patients with regard to patient characteristics, medication
and GP consultation (Table 3). Only two differences were
Table 1: Nonadherence in antidepressant use: results of the binomial multilevel analyses on early dropouts and continuers and on refill 
nonadherence
Early dropout (0 = continuer; 1 = early 
dropout)
Refill adherence (0 = adherent > 
80%; 1 = nonadherent)
Oddsratioa) 95% CI Oddsratioa) 95% CI
Socio-demographic characteristics
-age (mean; SD) 1.00 [0.99–1.01] 1.00 [1.00–1.00]
-% woman 0.78* [0.63–0.95] 1.00 [0.84–1.19]
-% college/university 1.05 [0.80–1.36] 0.86 [0.69–1.09]
-% non-western 2.47* [1.70–3.60] 2.59* [1.75–3.82]
-% private insurance 1.06 [0.85–1.33] 0.95 [0.78–1.15]
-% living together 1.02 [0.80–1.29] 1.00 [0.82–1.21]
-% with job/study 1.26 [1.00–1.60] 0.88 [0.73–1.07]
Use of medication
Antidepressants
- % users of SSRIs 0.80 [0.59–1.08] 1.27* [1.04–1.63]
- % users of TCAs 1.55* [1.14–2.11] 0.76* [0.58–0.99]
- % users of other antidepressants reference reference
Complex regime
number of other ATCs (mean;sd) 1.02 [1.00–1.05] 0.97* [0.95–0.99]
Health & morbidity in general 
practice
Self-reported health
% excellent/good 1.20 [0.98–1.47] 1.17 [0.99–1.37]
Diagnoses for which GP is consulted (% of 
patients)
Depression (P03/P76) 0.62* [0.50–0.76] 0.91 [0.77–1.07]
Anxiety (P01/P74) 0.75* [0.57–0.98] 1.15 [0.93–1.42]
Neurasthenia (P78) 2.01* [1.34–3.04] 0.82 [0.51–1.31]
Other diagnoses in P-chapter (P01–P99) 1.18 [0.95–1.47] 1.17 [0.97–1.41]
GP consultation for chronic diseases and overall 
contact
Number of other chronic complaints 
(mean, SD)
1.14* [1.05–1.24] 1.18* [1.09–1.27]
Number of contacts with GP (mean; SD) 0.99 [0.98–1.00] 0.99 [0.98–1.00]
Number of patients (N) 4,877 3,777
* P < 0.05
a) odds ratio > 1: more likely to be an early dropout; odds ratio < 1: less likely to be an early dropoutBMC Health Services Research 2007, 7:51 http://www.biomedcentral.com/1472-6963/7/51
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found in the multilevel analysis: patients who lived
together were less likely to be nonadherent to diabetes
medication compared to patients who lived alone. Diabe-
tes patients who visited their GP for cardiovascular dis-
eases were also less likely to be nonadherent (< 80%).
Since only 152 patients who used hypoglycemics were
nonadherent, we also estimated models with less varia-
bles. These analyses did not show different results. How-
ever, the analysis using 90% as a cut-off point for
nonadherence showed some extra correlates. Patients
who were older, had a paid job and a complex medication
regime were more often nonadherent.
Differences between practices
An additional objective of this study was to explore differ-
ences in adherence among patients from different general.
This was only calculated for the refill adherence outcome
measure since for early dropout the number of patients
per practice was generally low, leaving too few practices
for analyses. Table 4 shows that there was a considerable
range between general practices in the proportion of
patients who were nonadherent. Differences between gen-
eral practices were largest for hypoglycemics. This was
confirmed in a multilevel analysis in which we estimated
the 95% -confidence interval (CI-95%) for the proportion
of non-adherent patients. For antidepressants CI-95% was
65–83%, for hypertension 74–95% and for oral hypogly-
cemics 73–98%. Moreover, analysis including patient
characteristics showed that this variation cannot be
explained by differences in patient population.
There is a positive correlation between the proportion of
adherent patients between the three drug groups, which is
statistically significant (P < 0.05) for the association
between 1) antidepressants and hypoglycemics (r = 0.39)
and 2) antihypertensives and hypoglycemics (r = 0.53).
Table 2: Nonadherence in antihypertensive use: results of the binomial multilevel analyses on early dropouts and continuers and on 
refill nonadherence
Early dropout (0 = continuer; 1 = early 
dropout)
Refill adherence (0 = adherent > 
80%; 1 = nonadherent)
Odds ratioa) 95% CI Odds ratioa) 95% CI
Socio-demographic characteristics
- age (mean; SD) 0.95* [0.95–0.96] 1.00 [0.99–1.00]
- % woman 1.29* [1.09–1.54] 1.08 [0.95–1.23]
- % college/university 1.34* [1.06–1.69] 1.04 [0.85–1.27]
- % non-western 2.22* [1.53–3.24] 1.44 [0.97–2.15]
- % private insurance 1.12 [0.93–1.35] 1.09 [0.95–1.25]
- % living together 0.94 [0.71–5.17] 0.88 [0.77–1.02]
- % with job/study 1.08 [0.88–1.32] 1.07 [0.89–1.27]
Medication
Antihypertensives
- % users of beta blockers 0.59* [0.49–0.72] 0.50* [0.44–0.57]
- % users of diuretics ref. reference
- % users of ace-inhibitors/A2 antagonists 0.25* [0.17–0.36] 0.37* [0.31–0.45]
- % users of other antihypertensives 0.58* [0.43–0.78] 0.30* [0.23–0.38]
Complex regime
number of other ATCs (mean;sd) 0.94* [0.92–0.96] 0.97* [0.96–0.99]
Health & morbidity in general practice
Self-reported health
% excellent/good 1.51* [1.27–1.81] 0.93 [0.82–1.05]
Diagnoses for which GP is consulted (% of patients)
Diabetes (T90) 0.46* [0.33–0.65] 0.69* [0.60–0.91]
Hypertension (K85–K87) 0.11* [0.08–0.13] 0.77* [0.64–0.78]
Other diagnoses in K-chapter (from K70–K99) 0.76* [0.62–0.78] 1.08 [0.98–1.24]
Hypercholesterolemia (T93) 0.50* [0.32–0.78] 0.88 [0.94–1.10]
GP consultation for chronic diseases and overall contact
Number of other chronic complaints (mean, SD) 1.11* [1.02–1.21] 1.04 [0.98–1.11]
Number of contacts with GP (mean; SD) 1.04* [1.03–1.05] 1.02* [1.01–1.03]
Total (%)
Number of patients (N) 14,219 12,110
* P < 0.05
a) odds ratio > 1: more likely to be an early dropout; odds ratio < 1: less likely to be an early dropoutBMC Health Services Research 2007, 7:51 http://www.biomedcentral.com/1472-6963/7/51
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These findings suggest that high adherence rates are at
least partly a characteristic of the general practice.
Discussion
This study found generally lower nonadherence rates
compared to previous research for each of the three dis-
eases [2]. However, definitions of nonadherence varied
strongly across previous studies. The reason why we found
lower rates of nonadherence may be that that we focused
on early dropout and refill adherence < 80%. Moreover,
our pharmacy record data did not include a measure for
primary nonadherence, where the patient does not
redeem the prescription [15]. In the dataset that was the
source for this study, 7.6% of all prescriptions were not
redeemed [16]. In absolute numbers beta blockers and
antidepressants were among the top of non-redeemed
drugs. However, these drugs also have a high prescription
volumes in the Netherlands [17].
Correlates for serious nonadherence
One of the aims of our study was to find out whether risk
profiles for nonadherence were comparable for patients
Table 4: Percentage of patients who were adherent (refill adherence) per general practicea) and correlations between drugsb)
Type of drug Proportion of adherent patients 95% CI interval Correlations between drugs (for practices > 10 patients) N
Antihyper- tensives Antidepressants
Hypoglycemics 90.7 73–98% 0.53* 0.39* 65
Antihypertensives 86.7 74–95% 0.24 72
Antidepressants 77.9 65–83% 69
* p < 0.01
a) estimated with a multilevel model (empty model)
b) estimated at the practice level
Table 3: Refill adherence to oral hypoglycemics: differences between adherent and nonadherent patients
Bivariate analyses Multilevel logistic analysis (multivariate; 
0 = adherent; 1 = nonadherent)
Nonadherent patients Adherent patients Oddsratioa) 95% CI
Socio-demographic characteristics
- age in years (mean; SD) 66.6 (13.4) 65.8 (11.9) 1.01 [0.99–1.03]
- % woman 59.2 52.9 1.22 [0.82–1.82]
- % college/university 6.6 8.4 0.85 [0.40–1.82]
- % non-western 9.9 7.1 1.49 [0.76–2.91]
- % private insurance 19.7 23.9 0.75 [0.47–1.22]
- % living together 63.8* 73.5 0.65* [0.43–0.97]
- % with job/study 19.1 17.9 1.68 [0.94–3.00]
Use of medication
Complex regime
number of other ATCs (mean;sd) 8.4 (6.0) 7.5 (5.3) 1.04 [0.99–1.08]
Health & morbidity in general practice
Self-reported health
% excellent/good 36.2 44.0* 0.75 [0.51–1.11]
Diagnoses for which GP is consulted (% of patients)
Diabetes (T90) 84.2 88.2 0.69 [0.41–1.17]
Hypertension (K85–K87) 28.9 32.7 0.77 [0.51–1.17]
Other diagnoses in K-chapter (from K70–K99) 21.1 25.8 0.60* [0.37–0.98]
Hypercholesterolemia (T93) 11.2 11.9 0.96 [0.52–1.77]
GP consultation for chronic diseases and overall contact
Number of other chronic complaints (mean, SD) 0.7 (0.9) 0.7 (1.0) 0.87 [0.70–1.07]
Number of contacts with GP (mean; SD) 12.7 (10.8) 12.3 (9.9) 1.01 [0.98–1.03]
Total (%) 6.9
Number of patients (N) 152 2,042 2,194
* P < 0.05
a) odds ratio > 1: more likely to be nonadherent; odds ratio < 1: less likely to be nonadherentBMC Health Services Research 2007, 7:51 http://www.biomedcentral.com/1472-6963/7/51
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who used drugs for the following three chronic diseases:
depression (antidepressants), hypertension (antihyper-
tensives) and type 2 diabetes (oral hypoglycemics). Our
main conclusion is that no such common risk profile
emerges even when using the same source population and
measurements. For different diseases and its related med-
ication risk profiles differ and, therefore, nonadherence
should be studied and treated disease-specific.
For oral hypoglycemics few correlates for nonadherence
were found. On the contrary, early dropout from antihy-
pertensive use was correlated with many factors. Hence,
the question is whether these are indeed risk factors. For
example, younger and highly educated patients were more
likely to stop using antihypertensives at an early stage.
These patients may find other ways to lower their blood
pressure, for example by losing weight or doing more
exercises.
We did find some important correlates for nonadherence
to antidepressants and refill nonadherence to antihyper-
tensives. First of all, we found that non-western immi-
grants were more vulnerable for nonadherence to both
antihypertensives and antidepressants. This can be related
to their socio-economic status but also to a lack of under-
standing about their disease and its treatment since not all
immigrants are able to communicate easily in Dutch or
English. Both poor socio-economic status and poor
understanding are found to be related to lack of adherence
in antihypertensives in previous studies [2,18]. Our find-
ings cannot be attributed to moving out of the country
and, therefore, out of the registration databases because
non-western immigrants in the Netherlands have low
emigration rates. In 2001, the year of our study, only 1%
of Dutch non-western immigrants left the countr [19].
Our study also showed that in a primary care setting, type
of medication is associated with nonadherence to both
antidepressants and antihypertensives. Early discontinua-
tion was higher among TCA-users. This may be due to the
fact that TCAs are more often prescribed for other diag-
noses such as pain, and ensuresis (in children). Once
patients took antidepressants more continuously, users of
TCAs proved to be most adherent users of antidepressants.
This may be attributed to the fact that TCAs are more often
subject to discontinuation because of side effects as was
shown in a meta-analysis that compared treatment dis-
continuation of SSRIs and TCAs [20,21]. Once patients
overcome the first prescriptions and either do not have
side effects or accept them they may be more inclined to
take the medication. For antihypertensives users of ace-
inhibitors or/A2 antagonists were most adherent and type
of medication proved to be the strongest correlate for
adherence to antihypertensives. Nonadherence was high-
est among users of diuretics, which is in line with an ear-
lier study in the Netherlands [22]. Studies from other
countries not always found higher nonadherence rates for
diuretics [23]. Lower adherence to diuretics is, for exam-
ple, attributed to adverse effects and easiness of taking
medication.
GP consultation is important for adherence to antihyper-
tensives. Users of antihypertensives who visited their GP
for hypertension and/or diabetes had higher adherence
rates than patients who only had repeat medications
(either from the GP or the medical specialist). This stresses
the importance of communication about disease and
treatment. Communication is facilitated by face-to-face
consultation.
Somatic co-morbidity is associated with adherence to
antidepressants: patients with somatic co-morbidity were
more often seriously nonadherent. Since we controlled
for complex medication regime (number of different type
of drugs within a year) this effect cannot be attributed to
difficulties encountered in taking multiple medications.
In sum
For each definition of nonadherence we found that the
nonadherent patient population is hard to characterize by
its sociodemographic characteristics, GP consultation,
and medication related information on the patient, espe-
cially since correlates – partly – vary across diseases. A pre-
scriber determine out characteristics such as
sociodemographics ans GP consultation pattern rather
easily. However, adherence is probably also influenced by
patient characteristics that are less visible and more subtle,
for example the patients' attitudes towards taking medica-
tion or the patients' trust in the health care system [2].
These characteristics are more difficult to detect and need
more time and attention from prescribers.
Differences between practices
We found that adherence rates vary across general prac-
tices, even though the number of general practices
included in the analysis was low (n = 72). Previous studies
found that clear instructions on the management of dis-
ease has a positive impact on patient adherence [24] as
has a good relationship between prescriber and patient
[25]. Communication styles are found to differ between
doctors [26,27]. Future research should therefore further
unravel what characteristics and mechanisms cause
patients from one general practice to be more adherent
compared to patients listed in another practice.
Strengths and limitations of the study
This study used a population-based dataset with a large
sample, that enabled a multilevel analysis. Moreover, we
combined registration information with data from a
patient census, providing us with more information on
the patient than most regular registration databases. How-BMC Health Services Research 2007, 7:51 http://www.biomedcentral.com/1472-6963/7/51
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ever, our database also has some limitations. Dispensing
general practices were excluded from the database, while
about 10% of the patients in the Netherlands is listed in
such practice. Moreover, not all patients could be linked.
This was mainly due to the available linking keys [10,28].
The way the data were linked caused that the database
included more patients with chronic medication. As our
study included drugs that should be taken chronically,
such bias towards our study is expected to be limited. We
also had to exclude almost 30% of the (linked) patients
for whom we had dispensing data and consultation data
because these patients did not fill out the census form
with patient characteristics. However, these patients did
not differ in adherence rates from the patients who were
included in the study.
A main advantage of refill data is that adherence rates can
be estimated without the patient being aware of it. It
increases the accuracy of the estimates by eliminating any
Hawthorne effect [29]. Moreover, we used the medication
refill adherence measurement (MRA), which is, according
to a study by Hess et al [30] the preferred measure of
adherence when using administrative data. The use of
administrative pharmacy data also has some disadvan-
tages. The first problem is that it is not possible to assess
time of dosing [31,32] and that the data do not absolutely
reflect patients' drug use. Roter et al (1998) suggested that
prescription refills reflect patients' intention to comply
rather than their actual drug consumption, i.e. patients fill
their prescriptions more readily than they consume their
medicine [33]. However, some authors argue that patterns
of ongoing prescription refilling probably provide the
most accurate estimate of actual medication use in large
populations [34] , to assess drug exposure retrospectively
or when direct measurement of medication is not feasible
[31]. A recent study on hypertension medication found
that compliance measured by electronic monitoring
revealed higher adherence rates compared to prescription
refills [34]. The researchers argued that the reason for this
finding may be that electronic monitoring systems make
patients aware of taking medication and as such influence
adherence.
The data in our study refer mainly to the year 2001,
because patient characteristics and morbidity data in gen-
eral practice were only collected for that year. A one-year
period may seem short to study adherence patterns. How-
ever, for refill adherence we only included patients with at
least three prescriptions, which – given the fact that repeat
prescriptions in the Netherlands often are prescribed for a
three month period – covers about the whole year. In fact,
this definition of refill adherence refers to patients who
are inclined to used their medication but – in case they are
nonadherent – who fail to do so.
Another problem is that the data do not tell what the rea-
son for discontinuation is. Doctors may as well decide to
stop the medication rather than the patient. As such we
could not distinguish between a gap due to lack of adher-
ence and a gap due to medical decisions. Since we
expected this problem to be larger in the first stage of med-
ication use, we separately analyzed early dropout from
refill adherence. If a patient has three prescriptions over a
one-year course (which was the minimal number of pre-
scriptions for us to calculate refill adherence) we expect
that there is an intention to continue the treatment. More-
over, our results showed that patients who consult their
GP for complaints related to their medication (hyperten-
sion, anxiety, diabetes) are more compliant, which may
be an indication that GPs are not very much inclined to
stop the medication. Still, part of the discontinuation may
be due to medical decisions and therefore, estimates for
nonadherence in our study will be biased and – in real –
levels of adherence will be higher. This may be especially
true for antidepressants because this medication is not
always chronic. However, over 80% of antidepressant
users with three or more prescriptions in 2001 also had an
antidepressant prescription in 2002, indicating that for
the majority of patients there is an intention to continue
treatment. A final disadvantage of the use of dispensing
data is that such data do not reflect primary nonadher-
ence.
Implications for clinical practice and future research
For health care professionals it is hard to recognize non-
adherent patients by their socio-demographic back-
ground. Moreover, socio-demographics that are correlated
with nonadherence vary across different types of drugs.
There is an exception, though: patients' ethnic back-
ground. Non-western immigrants have lower levels of
adherence. In order to get insight into motivations of
these patients to be nonadherent it is important to check
upon and discuss this issue in patient-prescriber consulta-
tions: did they not understand why taking their medica-
tion is important, did they not agree upon taking
medication etc. Cultural aspects may influence the atti-
tude towards taking medication, an aspect we did not
include in our study [35]. In fact, regular monitoring of
and discussion on nonadherence is important for all
patients.
We argue that guidelines for prescribers should include
information on levels of nonadherence to certain types of
medication. For example, the Dutch GP guideline for
hypertension recommends diuretics as first choice medi-
cation in hypertension treatment. Our analyses showed
that in Dutch general practice adherence to diuretics is
lower than that to any other antihypertensive. For patients
who are suspected by the prescriber to be nonadherent it
may be more rational to prescribe a beta-blocker or anBMC Health Services Research 2007, 7:51 http://www.biomedcentral.com/1472-6963/7/51
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ace-inhibitor. At least prescribers should be aware of the
nonadherence problem with this type of medication and
closely monitor medication use. Such monitoring should
include questions on adverse effects and or experiences in
taking the medication during follow-up consultations.
Most of the implications mentioned refer to the impor-
tance of communication between professionals and
patients. The fact that prescribers vary when it comes to
their patients' adherence levels might, at least partly, be
explained by differences in communication styles
between prescribers. Further research into these differ-
ences among prescribers should provide more insight into
this issue.
Conclusion
No clear risk profiles for nonadherence could be con-
structed. Characteristics that were correlated with nonad-
herence varied across different types of medication.
Moreover, both patient and prescriber influence adher-
ence. Especially non-western immigrants need more
attention with regard to nonadherence, for example by
better monitoring or communication. Better insight into
the role of the prescriber in explaining variation in adher-
ence to medication is needed.
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